Edition:
United States

BioScrip Inc (BIOS.OQ)

BIOS.OQ on NASDAQ Stock Exchange Global Select Market

2.89USD
29 Sep 2016
Change (% chg)

$-0.03 (-1.03%)
Prev Close
$2.92
Open
$2.95
Day's High
$2.95
Day's Low
$2.86
Volume
78,801
Avg. Vol
204,858
52-wk High
$3.09
52-wk Low
$1.20

Latest Key Developments (Source: Significant Developments)

Bioscrip And Home Solutions enter deal to expedite closing
Friday, 2 Sep 2016 04:05pm EDT 

Press Release : Bioscrip and home solutions enter into amended asset purchase agreement to expedite closing . Co, hs infusion holdings inc further amended terms of their asset purchase agreement dated june 13, 2016 .Amended agreement to eliminate condition to closing that co receive stockholder approval to increase authorized share capital.  Full Article

Bioscrip enters into a tax asset protection plan
Friday, 12 Aug 2016 06:50am EDT 

Bioscrip Inc : Tax asset protection plan to protect company's ability to "utilize its net operating loss carryforwards" which total approximately $275 million . Bioscrip enters into a tax asset protection plan to protect its valuable tax assets . Will distribute to stockholders non-taxable dividend distribution of 1 preferred stock purchase right for each share of common stock of Co .Tax asset protection plan intended to act as "deterrent" to any person acquiring beneficial ownership of 4.9% or more of Co's common stock.  Full Article

North Tide Capital Master reports a passive stake of 7.5 pct in Bioscrip Inc
Monday, 27 Jun 2016 04:08pm EDT 

Bioscrip Inc :North Tide Capital Master LP reports a passive stake of 7.5 percent in Bioscrip Inc as of June 17, 2016 - SEC filing.  Full Article

BioScrip prices 40 mln shares offering at $2.00 per share
Thursday, 16 Jun 2016 10:20pm EDT 

BioScrip Inc : Says offering of 40.0 million common shares priced at $2.00 per share . Says expects to receive approximately $73.38 million in net proceeds from offering after deducting underwriting discounts .BioScrip prices underwritten offering of common stock.  Full Article

BioScrip to acquire Home Solutions
Monday, 13 Jun 2016 06:02am EDT 

BioScrip Inc : Total transaction consideration of $85.0 million . Will acquire substantially all of assets and assume certain liabilities of Home Solutions and its subsidiaries . Deal includes additional contingent consideration in form of restricted stock units . Closing consideration will consist of $80.0 million payable in cash, subject to certain adjustments and $5.0 million in shares . BioScrip inc says upon completion of transaction, Daniel Greenleaf will become chief executive officer of BioScrip . Upon completion of transaction, Daniel Greenleaf will become chief executive officer of BioScrip and join company's board . Rick Smith, director and chief executive officer of BioScrip will become vice chairman of board of directors . Jeffrey Kreger, chief financial officer of BioScrip, will serve as combined company's chief financial officer . BioScrip will continue to be headquartered in Denver, Colorado and plans to maintain branches throughout United States . Transaction is anticipated to be financed through net proceeds from an equity offering . Jefferies LLC is acting as financial advisor to BioScrip . Houlihan Lokey is acting as financial advisor to Home Solutions .BioScrip announces transformative acquisition of Home Solutions that will enhance focus as home infusion leader.  Full Article

Bioscrip announces proposed public offering of common stock
Monday, 13 Jun 2016 06:00am EDT 

Bioscrip Inc : Commenced an underwritten public offering of its common stock .Bioscrip announces proposed public offering of common stock.  Full Article

BioScrip Inc reaffirms FY 2016 EBITDA Guidance
Wednesday, 4 Nov 2015 07:00am EST 

BioScrip Inc:Reaffirms FY 2016 Adjusted EBITDA Guidance of Between $50 Million - $60 Million.  Full Article

BioScrip announces steps to enhance Shareholder Value
Monday, 10 Aug 2015 07:02am EDT 

BioScrip Inc:Announces steps to enhance shareholder value.Says implementing $35 million - $40 million in total cost savings over the next 12 months.Says provides full year 2016 EBITDA guidance of $50 - $60 million on revenues of $730 - $760 million.Says announces sale of non-core PBM business.Says retains Jefferies to explore strategic alternatives.Says names Chris Luthin as chief operating officer; engages Scott davido as chief implementation officer.To sell its non-core PBM business to Procare Pharmacy benefit manager inc for $25 million in cash.Proceeds from PBM business sale are projected to be used to pay down debt and support working capital needs.Says implementing reductions of approximately 12% of the workforce which will result in $19 million in total savings.Workforce reductions are expected to be completed by the end of the third quarter of 2015.Consolidating corporate functions in the company's Eden Prairie, minnesota facility and closing the Elmsford ny office by December.  Full Article

BioScrip appoints Veteran Finance Executive Jeffrey M. Kreger as Chief Financial Officer
Monday, 27 Apr 2015 07:00am EDT 

BioScrip Inc:Says that Jeffrey M. Kreger will join the Company as Senior Vice President, Chief Financial Officer and Treasurer, effective April 27.  Full Article

BioScrip raises $62.5 million in private placement of convertible preferred stock and announces plan for $20 million rights offering
Monday, 9 Mar 2015 09:34am EDT 

BioScrip Inc:Says sale of $62.5 million in Series A Convertible Preferred Stock to Coliseum Capital Management, LLC and affiliated funds.The Preferred Stock is convertible into 12,088,975 shares of BioScrip's common stock at conversion price of $5.17 per share, which was the closing price of BioScrip's common stock on NASDAQ Global Market on March 6.Dividends on the Preferred Stock will be payable quarterly at an annual rate of 8.5 pct if paid in cash or 11.5 pct if accrued.As part of the transaction, BioScrip issued to Coliseum Capital warrants for an aggregate of 3.6 million shares of BioScrip stock.Warrants for 1.8 million shares are exercisable at $5.295 per share and warrants for 1.8 million shares are exercisable at $6.596 per share.In addition, BioScrip intends to conduct a registered rights offering to allow all of BioScrip's existing stockholders of record, on date to be determined by the Board.The non-transferable right to purchase their pro rata share of $20.0 million of Preferred Stock and warrants on same terms as completed private placement to Coliseum Capital.Proceeds from private placement will be used primarily to reduce BioScrip's outstanding indebtedness.  Full Article

BRIEF-Bioscrip And Home Solutions enter deal to expedite closing

* Bioscrip and home solutions enter into amended asset purchase agreement to expedite closing